RWA
ATRS

River Wealth Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

River Wealth Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$1K – 541
2018
Q4 		$1K Hold
500
– – ﹤0.01% 532
2018
Q3 		$2K Hold
500
– – ﹤0.01% 548
2018
Q2 		$1K Buy
+500
New +$1.24K ﹤0.01% 566

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

River Wealth Advisors's ATRS Position: Q1 2019 in Review

River Wealth Advisors sold out of Antares Pharma, Inc. (ATRS) in Q1 2019, closing a stake of 500 shares — an estimated $1K sold.

River Wealth Advisors first reported a position in ATRS in Q2 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 132 funds tracked by Wall St. Rank hold ATRS as of Q1 2019.

  • River Wealth Advisors reported no remaining Antares Pharma, Inc. position as of Q1 2019 after selling out during the quarter.
  • River Wealth Advisors sold 500 Antares Pharma, Inc. shares in Q1 2019, an estimated $1K.
  • River Wealth Advisors first reported a position in Antares Pharma, Inc. in Q2 2018 and held it in 3 quarters.
  • River Wealth Advisors's Antares Pharma, Inc. position peaked at $2K in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2019.

Based on River Wealth Advisors's 13F filing for Q1 2019, filed 7 May 2019.